Born to HIV-Infected Mothers. It is possible that administration of an immunogenic vaccine can reduce the vertical transmission of HIV-1 or moderate its course in infected infants. Successful early sensitization to HIV epitopes might succeed in preventing HIV infection. Alternately, the enhancement of HIV-specific immune function might also succeed in modifying HIV replication and affecting disease progression.
Mothers serve as proxy for their infants.
Cohort 2 received a higher dose of vCP205. As of September 1999, infants are randomized to one of four new cohorts. All infants are followed every 2 weeks for the first 14 weeks of life, and then every 6 months until age 2. In addition, CD4 count, viral load, and mucosal antibody responses are measured. I A phase one trial is the first step on a drug's journey to approval.